PDCD1 and colorectal carcinoma: For patients with MSI-H/dMMR tumors, the introduction of PD-1 inhibitors has transformed the prognosis from less-than-one-year survival to five-year survival rates exceeding 55% [127], validating the concept of “durable benefit” and establishing immunotherapy as the backbone of treatment in this molecular subset of CRC.